HOME >> BIOLOGY >> NEWS
New study identifies factors associated with incomplete chemotherapy for colon cancer

Physical frailty, treatment complications, and lack of social and psychological support may explain why elderly stage III colon cancer patients do not complete a course of chemotherapy after surgery, according to a study in the May 3 Journal of the National Cancer Institute.

Several trials in the late 1980s led a 1990 National Institutes of Health Consensus Panel to recommend adjuvant chemotherapy, or chemotherapy given after surgical removal of a tumor, for stage III colon cancer patients. However, despite recommendations, many patients do not initiate or complete adjuvant chemotherapy.

Sharon Dobie, M.D., of the University of Washington in Seattle, and colleagues analyzed data from 3,193 stage III colon cancer patients from the Surveillance, Epidemiology, and End Results (SEER) registries, who began adjuvant chemotherapy treatments. Patients, identified through Medicare claims, were assessed by whether they completed their chemotherapy treatment, as well as by their sociodemographic, clinical, and environmental characteristics and their physicians' characteristics.

The authors found that of the 3,193 patients who chose to initiate chemotherapy, 2,497 (78.2%) of patients completed a course of adjuvant chemotherapy. Patients who completed adjuvant chemotherapy had a reduced risk of death. An incomplete course of chemotherapeutic treatment was associated with factors related to physical frailty, treatment complications, and a lack of social and psychological support. Their physicians' characteristics did not affect whether they completed chemotherapy. African-Americans were equally likely to finish treatment as Caucasians.

The authors write, "From these findings, interventions to improve social and physical support throughout the treatment course could be implemented to test whether such support improves rates of chemotherapy completion in elderly colon cancer patients."

In an accompanying editorial, Victor R. Grann,
'"/>

Contact: Ariel Whitworth
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
2-May-2006


Page: 1 2

Related biology news :

1. New study warns limited carbon market puts 20 percent of tropical forest at risk
2. Clones on task serve greater good, evolutionary study shows
3. Pollution causes 40 percent of deaths worldwide, study finds
4. A study by the MUHC and McGill University opens a new door to understanding cancer
5. New study suggests Concord grape juice may provide protection against breast cancer
6. Preclinical study links gene to brain aneurysm formation
7. In limiting life span, study finds booming bacteria innocent
8. Multicenter study nets new lung tumor-suppressor gene
9. MIT study: Maturity brings richer memories
10. Chickadee, nutchatch presence in conifers increases tree growth, says CU-Boulder study
11. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: